DexCom, Inc. (NASDAQ:DXCM) Shares Sold by National Pension Service

National Pension Service lessened its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 35.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 616,730 shares of the medical device company’s stock after selling 333,013 shares during the period. National Pension Service owned 0.16% of DexCom worth $47,963,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of DXCM. Private Advisor Group LLC raised its position in shares of DexCom by 5.7% during the 3rd quarter. Private Advisor Group LLC now owns 11,318 shares of the medical device company’s stock worth $759,000 after purchasing an additional 608 shares during the last quarter. International Assets Investment Management LLC purchased a new stake in DexCom during the 3rd quarter valued at about $930,000. State of Alaska Department of Revenue grew its stake in DexCom by 7.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 46,400 shares of the medical device company’s stock valued at $3,110,000 after acquiring an additional 3,155 shares in the last quarter. abrdn plc grew its stake in DexCom by 28.4% during the 3rd quarter. abrdn plc now owns 384,646 shares of the medical device company’s stock valued at $25,842,000 after acquiring an additional 85,174 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in DexCom by 103.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,306 shares of the medical device company’s stock valued at $356,000 after acquiring an additional 2,692 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on DXCM shares. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Morgan Stanley upped their price objective on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Finally, Canaccord Genuity Group increased their price target on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average target price of $99.06.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the sale, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. This represents a 0.97 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 38,083 shares of company stock worth $3,309,794 in the last ninety days. 0.30% of the stock is owned by corporate insiders.

DexCom Stock Performance

NASDAQ:DXCM opened at $87.81 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The stock has a market capitalization of $34.31 billion, a P/E ratio of 61.41, a PEG ratio of 2.30 and a beta of 1.14. The company has a 50 day moving average price of $84.53 and a 200 day moving average price of $76.55. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.